Report: Merck Searching Internally For Next CEO

Merck & Co., Inc. MRK is preparing for the departure of its CEO Kenneth Frazier and searching internally for a replacement, according to Bloomberg.

In May, Merck announced an agreement to acquire the clinical-stage biopharmaceutical company Peloton Therapeutics for $1.05 billion cash upfront and a further $1.15 billion if certain regulatory and sales milestones are reached.

On Wednesday, Merck & Co shares are trading up 0.19% at $84.66.

Related Links:

The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut

Merck To Buy Clinical-Stage Biopharma Peloton Therapeutics For More Than $1B

Photo courtesy of Merck. 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareManagementMediaGeneralBloomberg
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!